Financials Redx Pharma Plc London S.E.

Equities

REDX

GB00BSNB6S51

Biotechnology & Medical Research

Market Closed - London S.E. 16:46:01 30/04/2024 BST 5-day change 1st Jan Change
15 GBX +31.58% Intraday chart for Redx Pharma Plc -.--% -31.82%

Valuation

Fiscal Period: September 2021 2022 2023 2024 2025
Capitalization 1 271.2 206.7 95.78 64.96 -
Enterprise Value (EV) 2 255.8 168.6 93.42 60.15 104.1
P/E ratio - - - - -
Yield - - - - -
Capitalization / Revenue 27 x 11.1 x 22.8 x 5.2 x -
EV / Revenue 25.5 x 9.02 x 22.2 x 4.81 x -
EV / EBITDA -13.4 x -11 x -3.07 x -2.32 x -2.1 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - - - - -
Nbr of stocks (in thousands) 275,282 333,353 334,911 388,986 -
Reference price 3 0.9850 0.6200 0.2860 0.1670 0.1670
Announcement Date 27/01/22 20/12/22 15/12/23 - -
1EUR in Million2GBP in Million3
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net sales 1 3.131 5.685 10.04 18.69 4.202 12.5 -
EBITDA 1 - -7.536 -19.11 -15.38 -30.47 -25.92 -49.67
EBIT 1 - -8.518 -19.74 -16.27 -31.43 -26.8 -50.55
Operating Margin - -149.83% -196.76% -87.03% -747.91% -214.4% -
Earnings before Tax (EBT) 1 - -9.168 -21.44 -17.8 -32.79 -26.81 -50.56
Net income 1 - -9.213 -21.58 -18 -33.16 -26.14 -49.3
Net margin - -162.06% -215.01% -96.33% -789.05% -209.12% -
EPS - - - - - - -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 16/03/20 27/01/21 27/01/22 20/12/22 15/12/23 - -
1GBP in Million
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - 39.1
Net Cash position 1 - 7.04 15.3 38.1 2.36 4.81 -
Leverage (Debt/EBITDA) - - - - - - -0.7876 x
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - 0.06 0.75 0.26 - 0.26 0.26
Capex / Sales - 1.04% 7.51% 1.4% - 2.08% -
Announcement Date 16/03/20 27/01/21 27/01/22 20/12/22 15/12/23 - -
1GBP in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings